News & Events

Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer

Genentech’s Divarasib Delivers Phase III Survival Benefit in KRAS G12C Non-Small Cell Lung Cancer

Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer

Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer

Roche Divarasib Beats Approved KRAS Inhibitors in Phase III

Roche Divarasib Beats Approved KRAS Inhibitors in Phase III

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche s Divarasib Shows Promising Results in Advancing Lung Cancer Treatment for KRAS G12C Patients

Roche s Divarasib Shows Promising Results in Advancing Lung Cancer Treatment for KRAS G12C Patients

Roche Reports P-III (Krascendo 1) Trial Results on Divarasib for KRAS G12C-Mutant NSCLC

Roche Reports P-III (Krascendo 1) Trial Results on Divarasib for KRAS G12C-Mutant NSCLC

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study

Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Genentech’s KRAS G12C inhibitor divarasib shines in NSCLC phase III

Genentech’s KRAS G12C inhibitor divarasib shines in NSCLC phase III